Cargando…

Two patients walk into a clinic...a genomics perspective on the future of schizophrenia

Progress is being made in schizophrenia genomics, suggesting that this complex brain disorder involves rare, moderate to high-risk mutations and the cumulative impact of small genetic effects, coupled with environmental factors. The genetic heterogeneity underlying schizophrenia and the overlap with...

Descripción completa

Detalles Bibliográficos
Autor principal: Corvin, Aiden P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3214150/
https://www.ncbi.nlm.nih.gov/pubmed/22078159
http://dx.doi.org/10.1186/1741-7007-9-77
_version_ 1782216210074566656
author Corvin, Aiden P
author_facet Corvin, Aiden P
author_sort Corvin, Aiden P
collection PubMed
description Progress is being made in schizophrenia genomics, suggesting that this complex brain disorder involves rare, moderate to high-risk mutations and the cumulative impact of small genetic effects, coupled with environmental factors. The genetic heterogeneity underlying schizophrenia and the overlap with other neurodevelopmental disorders suggest that it will not continue to be viewed as a single disease. This has radical implications for clinical practice, as diagnosis and treatment will be guided by molecular etiology rather than clinical diagnostic criteria.
format Online
Article
Text
id pubmed-3214150
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32141502011-11-12 Two patients walk into a clinic...a genomics perspective on the future of schizophrenia Corvin, Aiden P BMC Biol Opinion Progress is being made in schizophrenia genomics, suggesting that this complex brain disorder involves rare, moderate to high-risk mutations and the cumulative impact of small genetic effects, coupled with environmental factors. The genetic heterogeneity underlying schizophrenia and the overlap with other neurodevelopmental disorders suggest that it will not continue to be viewed as a single disease. This has radical implications for clinical practice, as diagnosis and treatment will be guided by molecular etiology rather than clinical diagnostic criteria. BioMed Central 2011-11-11 /pmc/articles/PMC3214150/ /pubmed/22078159 http://dx.doi.org/10.1186/1741-7007-9-77 Text en Copyright ©2011 Corvin; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Opinion
Corvin, Aiden P
Two patients walk into a clinic...a genomics perspective on the future of schizophrenia
title Two patients walk into a clinic...a genomics perspective on the future of schizophrenia
title_full Two patients walk into a clinic...a genomics perspective on the future of schizophrenia
title_fullStr Two patients walk into a clinic...a genomics perspective on the future of schizophrenia
title_full_unstemmed Two patients walk into a clinic...a genomics perspective on the future of schizophrenia
title_short Two patients walk into a clinic...a genomics perspective on the future of schizophrenia
title_sort two patients walk into a clinic...a genomics perspective on the future of schizophrenia
topic Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3214150/
https://www.ncbi.nlm.nih.gov/pubmed/22078159
http://dx.doi.org/10.1186/1741-7007-9-77
work_keys_str_mv AT corvinaidenp twopatientswalkintoaclinicagenomicsperspectiveonthefutureofschizophrenia